Praxis Precision Medicines, Inc. (PRAX) |
|
2.125 -0.065 (-2.97%)
|
12-05 13:21 |
|
Open: |
2.21 |
Pre. Close: |
2.19 |
|
High:
|
2.21 |
Low:
|
2.0947 |
|
Volume:
|
78,787 |
Market Cap:
|
100(M) |
|
|
|
Technical analysis |
as of: 2022-12-05 1:22:04 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 2.68 One year: 3.02 |
| Support: |
Support1: 1.83 Support2: 1.52 |
| Resistance: |
Resistance1: 2.29 Resistance2: 2.58 |
| Pivot: |
2.06  |
| Moving Average: |
MA(5): 2.17 MA(20): 2.09
MA(100): 2.76 MA(250): 7.49 |
| MACD: |
MACD(12,26): 0 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 63.9 %D(3): 56.2 |
| RSI: |
RSI(14): 54.7 |
| 52-week: |
High: 20.85 Low: 1.48 |
| Average Vol(K): |
3-Month: 656 (K) 10-Days: 301 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PRAX ] has closed below upper band by 24.9%. Bollinger Bands are 61.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.24 - 2.25 |
2.25 - 2.25 |
|
Low:
|
2.04 - 2.05 |
2.05 - 2.06 |
|
Close:
|
2.17 - 2.19 |
2.19 - 2.2 |
|
Company Description |
|
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts. |
Headline News |
Thu, 01 Dec 2022
William Blair Comments on Praxis Precision Medicines, Inc.'s FY2022 Earnings (NASDAQ:PRAX) - MarketBeat
Mon, 28 Nov 2022
Praxis Precision Medicines to Advance PRAX-562 Phase 2 Study in Pediatric Patients with Developmental and Epileptic Encephalopathies - GlobeNewswire
Tue, 22 Nov 2022
What is the Market's View on Praxis Precision Medicines Inc (PRAX) Stock's Price and Volume Trends Tuesday? - InvestorsObserver
Tue, 22 Nov 2022
Liquid Argon Market Will Hit Big Revenues In Future | Prax Air, The Linde Group, Hesser, Yingde gases group, B - openPR
Thu, 10 Nov 2022
Is Praxis Precision Medicines Inc (PRAX) a Winner in the Biotechnology Industry? - InvestorsObserver
Thu, 10 Nov 2022
Prax looks towards cleaner fuels and methods with revenues of £4.6b in first year of refinery operations - Business Live
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
47 (M) |
| Shares Float |
36 (M) |
|
% Held by Insiders
|
0.6 (%) |
|
% Held by Institutions
|
91 (%) |
|
Shares Short
|
2,100 (K) |
|
Shares Short P.Month
|
2,050 (K) |
Stock Financials |
|
EPS
|
-4.72 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
2.24 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-62.7 |
|
Return on Equity (ttm)
|
-115.5 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-4.9 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-201 (M) |
|
Levered Free Cash Flow
|
-116 (M) |
Stock Valuations |
|
PE Ratio
|
-0.47 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.97 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-0.51 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
